Yi M, Jiao D, Qin S, Chu Q, Wu K, Li A. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer. 2019;18(1):60. https://doi.org/10.1186/s12943-019-0974-6.

Article  PubMed  PubMed Central  Google Scholar 

Liu R, et al. IMM2510, an anti-PD-L1/VEGF bispecific antibody fusion protein, in patients with advanced solid tumors: a phase I dose-escalation study. J Clin Oncol. 2024;42(16_suppl):e14506–e14506. https://doi.org/10.1200/JCO.2024.42.16_suppl.e14506.

Article  Google Scholar 

Wu L, et al. Efficacy and safety of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with solid tumors: clinical data from advanced cervical cancer and platinum-resistant recurrent ovarian cancer cohorts. J Clin Oncol. 2024;42(16_suppl):5524–5524. https://doi.org/10.1200/JCO.2024.42.16_suppl.5524.

Article  Google Scholar 

Wu C, et al. A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced NSCLC. J Clin Oncol. 2024;42(16_suppl):8533–8533. https://doi.org/10.1200/JCO.2024.42.16_suppl.8533.

Article  Google Scholar 

Falchook GS, et al. Phase 1 trial safety and efficacy of ragistomig, a bispecific antibody targeting PD-L1 and 4–1BB, in advanced solid tumors. J Clin Oncol. 2024;42(16_suppl):2529–2529. https://doi.org/10.1200/JCO.2024.42.16_suppl.2529.

Article  Google Scholar 

Lin T, et al. A phase 1, dose escalation/dose-expansion study of QLF31907, a bispecific antibody (BsAb) targeting PD-L1 and 4-1BB, in patients with advanced solid tumors and lymphoma. J Cli Oncol. 2024;42(16_suppl):2534–2534. https://doi.org/10.1200/JCO.2024.42.16_suppl.2534.

Article  Google Scholar 

M. Lu et al., 2024 “A novel and uniquely designed bispecific antibody (LBL-024) against PD-L1 and 4–1BB in patients with advanced malignant tumors and neuroendocrine carcinoma: A report of safety and robust efficacy of LBL-024 monotherapy in phase I/II, first-in-human, open-label, multicenter, dose escalation/expansion study.,” J Clin Oncol. 42 16_suppl: 4010–4010. https://doi.org/10.1200/JCO.2024.42.16_suppl.4010.

Kyi C, et al. Phase I study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab. J Clin Oncol. 2024;42(16_supp):2520–2520. https://doi.org/10.1200/JCO.2024.42.16_suppl.2520.

Article  Google Scholar 

Garralda E, et al. First-in-human study (FIH) of FS222, a next-generation tetravalent PD-L1/CD137 bispecific antibody: Safety, pharmacodynamics (PD), and antitumor activity in patients (pts) with advanced solid tumors including PD-1 refractory melanoma. J Clin Oncol. 2024;42(16_suppl):2505–2505. https://doi.org/10.1200/JCO.2024.42.16_suppl.2505.

Article  Google Scholar 

Li X, et al. Effect of cancer immunotherapy with CD39/PD-L1 bispecific antibody OriA631-b. J Clin Oncol. 2024;42(16_suppl):e14508–e14508. https://doi.org/10.1200/JCO.2024.42.16_suppl.e14508.

Article  Google Scholar 

J. Xue et al., 2024 “Phase I/II safety and preliminary efficacy of PM1022, a bispecific antibody targeting PD-L1 and TIGIT, in patients with advanced solid tumors.,” J Clin Oncol. 42 16: e14694–e14694. https://doi.org/10.1200/JCO.2024.42.16_suppl.e14694.

Chamoto K, Hatae R, Honjo T. Current issues and perspectives in PD-1 blockade cancer immunotherapy. Int J Clin Oncol. 2020;25(5):790. https://doi.org/10.1007/s10147-019-01588-7.

Article  PubMed  PubMed Central  Google Scholar 

Cao F, et al. An open-label, single-center phase II trial of cadonilimab (an anti PD-1/CTLA-4 bispecific antibody) in combination with platinum-based dual drug neoadjuvant chemotherapy for locally advanced, resectable head and neck squamous cell carcinoma. J Clin Oncol. 2024;42(16_suppl):6044–6044. https://doi.org/10.1200/JCO.2024.42.16_suppl.6044.

Article  Google Scholar 

Fan S, Wang T, Zhang Q, Wang J, Su J, Liu Z. Safety and clinical activity of cadonilimab, an anti PD-1/CTLA-4 bispecific antibody, for patients with persistent, recurrent, or metastatic cervical cancer R/M CC A retrospective, real mworld study. J Clin Oncol. 2024;42(16_suppl):e17522–e17522. https://doi.org/10.1200/JCO.2024.42.16_suppl.e17522.

Article  Google Scholar 

Li J, et al. Prognostic analysis of PD-1/CTLA-4 bispecific antibody combined with chemotherapy first-line treatment for recurrent or metastatic cervical cancer: a multicenter real-world study. J Clin Oncol. 2024;42(16_suppl):e17520–e17520. https://doi.org/10.1200/JCO.2024.42.16_suppl.e17520.

Article  Google Scholar 

Jiao Z, et al. Neoadjuvant cadonilimab (PD-1/CTLA-4 bispecific antibody) plus FLOT chemotherapy in locally advanced gastric/gastroesophageal junction cancer (GC/GEJC): a prospective, multi-center, phase II study. J Clin Oncol. 2024;42(16_suppl):e16108–e16108. https://doi.org/10.1200/JCO.2024.42.16_suppl.e16108.

Article  Google Scholar 

Tang J, Tian W, Huang S, Yang J, Yang H, Zhang J. An open, prospective, single arm, phase II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) with neoadjuvant chemotherapy in patients with advanced ovarian cancer: interim analysis from the AK104-IIT-003 study. J Clin Oncol. 2024;42(16_suppl):e17552–e17552. https://doi.org/10.1200/JCO.2024.42.16_suppl.e17552.

Article  Google Scholar 

Han S, et al. Preliminary results from a phase II study to evaluate the efficacy and safety of perioperative disitamab vedotin (RC48-ADC) plus cadonilimab (AK104, PD-1/CTLA 4 bispecific antibody) for HER2-expressing muscle-invasive bladder cancer (MIBC). J Clin Oncol. 2024;42(16_suppl):e16591–e16591. https://doi.org/10.1200/JCO.2024.42.16_suppl.e16591.

Article  Google Scholar 

Wahafu W, et al. Disitamab vedotin (DV, RC48-ADC) combined with cadonilimab (anti-PD-1/CTLA-4 bispecific antibody) in patients with locally advanced or metastatic urothelial carcinoma (la/mUC) An open-label, single-arm, phase II study. J Clin Oncol. 2024;42(16_suppl):e16572–e16572. https://doi.org/10.1200/JCO.2024.42.16_suppl.e16572.

Article  Google Scholar